President and Chief Executive Officer of BlueWillow Biologics.
Rebuilding Trust in Intranasal Vaccines for Avian Flu and Other Respiratory Diseases
November 12th 2024Chad Costley, MD, MBA, provided an update on BlueWillow Biologics' NanoVax intranasal vaccine for H5N1, with Phase 1 trial data showing broad immune responses and no serious adverse events.
Read More